How the commercialisation of gene and cell therapies can revolutionise modern medicine

‘If one or two CAR-T therapies get to market it will provide impetus and momentum behind the industry’ – Dr Akshay Peer, Vice President of Sales and Account Management at TrakCel discusses the revolutionary steps that cell and gene therapies are making through their increased commercialisation.

In a field that is constantly seeing developments, Dr Peer outlines CRISPR and CAR-T therapies as forms of gene editing that can dramatically change the face of gene therapies and their use within modern medicine. He believes that as the commercialisation of these treatments increases, the regularity of their use will as well.

This is due to the surge in ‘positive public opinion’ that will arise from the successful implementation of the therapies. Dr Peer identifies the positivity that already exists around the new therapies, with ‘everyone looking at when these therapies will come to market and how much they will cost’. Although not going into detail about the financial outcome, he outlines his hope that when the public can see the lives of adults and children enhanced by using these therapies, any uncertain opinions will change to ones of optimism and confidence.

Peer acknowledges the lack of information that can exist around the new therapies due to an unfamiliarity in their usage; ‘People can sometimes get ahead of themselves and not understand completely what we’re trying to do here in this industry’. However, he is sure that this will change once there is evidence of patients who are successfully treated.

There is clearly excitement developing around the use of gene therapies, outlined by Dr Peer.

Watch the full interview, filmed at Cell Therapy Manufacturing & Gene Therapy Congress, with Dr Peer above or here.

Commercialisation of Cell and Gene Therapies [Whitepaper]

Whitepaper Overview:

The global market for cell – based therapies is expected to surpass the $20 billion USD mark by 2025, with an annual growth rate of 21%. The main targets for cell – based therapies are high impact disease areas with significant unmet needs, including cancer, heart disease, neurodegenerative diseases, musculoskeletal disorders and autoimmune diseases.


Examples of the landmarks attained are: 1) In order to accelerate a cure for diabetes, Harvard Stem Cell Institute, and Semma Therapeutics developed a process to generate nearly unlimited numbers of beta cells for the clinic. 2) Vital Therapies enrolled First Patient in Phase III Liver-Treatment Trial, for company’s ELAD System, an extracorporeal human allogeneic cellular liver therapy (already tested successfully in over 250 patients). 3) PCT (Caladrius Biosciences, Inc. , NJ, US) enter an agreement with Kiadis Pharma (Netherlands) on engineering and process development for a Phase III trial of Kiadis’ lead product, ATIR101™, for the treatment of blood cancers, in US and Canada. 4) A broad collaboration agreement was established between Memorial Sloan-Kettering Cancer Center (MSK) and Seres Therapeutics, Inc. to develop microbiome therapeutics for hematopoietic stem cell transplantation (HSCT) and immuno-oncology treatment in patients with dysbiotic microbiome. The FDA has granted SER-109 (Seres’ most advanced program) ‘orphan drug’ and ‘breakthrough’ therapy designations. 5) Vital Therapies bio-therapeutic company enrolled first patient in phase III liver-treatment trial. The study will exploit company’s ELAD System, an extracorporeal human allogeneic cellular liver therapy. 6) SAB Biotherapeutics with the US Navy has successfully developed a transchromosomic (Tc) bovine platform technology to produce Human Polyclonal Antibodies against Ebola Zaire Virus. Continue reading “Commercialisation of Cell and Gene Therapies [Whitepaper]”